ARS Pharmaceuticals (SPRY) Depreciation and Depletion (2020 - 2024)
ARS Pharmaceuticals (SPRY) reported Depreciation and Depletion of $29000.0 for Q4 2024, up 141.67% on a YoY basis from $12000.0 in Q1 2024, and up 38.1% sequentially from $21000.0 in Q3 2024.
ARS Pharmaceuticals (SPRY) Depreciation and Depletion (2020 - 2024) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 5 years of Depreciation and Depletion data on file, last reported at $29000.0 in Q4 2024.
- For the quarter ending Q4 2024, Depreciation and Depletion rose 141.67% year-over-year to $29000.0; the trailing twelve-month figure through Dec 2024 stood at $79000.0 (up 8.22% YoY), and the FY2024 full-year result was $79000.0, up 8.22% from the prior year.
- Depreciation and Depletion grew to $29000.0 in Q4 2024, from $21000.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $209000.0 in Q2 2021 to a low of -$37000.0 in Q2 2022.
- A 5-year average of $79300.0 and a median of $25000.0 in 2023 frame the typical range for Depreciation and Depletion.
- Across the five-year window, Depreciation and Depletion tumbled 117.7% in 2022 and surged 200.0% in 2023, its largest moves.
- Tracing SPRY's Depreciation and Depletion over 5 years: stood at $152000.0 in 2020, then soared by 34.21% to $204000.0 in 2021, then tumbled by 93.14% to $14000.0 in 2022, then declined by 14.29% to $12000.0 in 2023, then jumped by 141.67% to $29000.0 in 2024.
- Business Quant data shows SPRY's Depreciation and Depletion at $29000.0 in Q4 2024, $21000.0 in Q3 2024, and $18000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 39.39 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 29,000.00 |
| Dec 31, 2024 | 29,000.00 |
| Sep 30, 2024 | 21,000.00 |
| Sep 30, 2024 | 21,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Mar 31, 2023 | 20,000.00 |
| Mar 31, 2023 | 20,000.00 |
| Dec 31, 2022 | 14,000.00 |
| Dec 31, 2022 | 14,000.00 |
| Sep 30, 2022 | 7,000.00 |
| Sep 30, 2022 | 7,000.00 |